Accessibility Menu
Metagenomi Therapeutics logo

Metagenomi Therapeutics(NASDAQ) MGX

Current Price$1.23
Market Cap$46.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-88%
5 YearN/A
1 Year-47%
1 Month+4%
Metagenomi Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 1.242026-07-22
Metagenomi Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-3.88%USD 1.292026-07-15
1 month+4.2%USD 1.192026-06-22
3 month-13.29%USD 1.432026-04-23
Year to date-23.46%USD 1.622025-12-31
1 year-46.78%USD 2.332025-07-22
Since inception-87.97%USD 10.312024-02-09

Metagenomi Therapeutics Financials at a Glance

Market Cap

$46.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$22.33M

Net Income (TTM)

-$85.89M

EPS (TTM)

-$2.29

P/E Ratio

-0.54

Dividend

$0.00

Beta (Volatility)

1.10 (Average)

Price

$1.23

Volume

13

Open

$1.30

Previous Close

$1.24

Daily Range

$1.20 - $1.30

52-Week Range

$1.13 - $3.95

Estimated Earnings Date

Aug 11, 2026

MGX News

group of scientists with microscopes lab testing

This Biotech IPO Stock Just Took a Tumble, But Don't Give Up on It Yet

Alex CarchidiFeb 19, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Metagenomi Therapeutics

Metagenomi develops gene editing tools to help treat genetic diseases. Its technology aims to fix faulty genes in patients. The company works with partners to create new therapies for conditions like hemophilia and cancer.

Gene Editing, Decoded: What Metagenomi Sells

  • Genome Editing Tools: Programmable enzymes that cut or change DNA, used by researchers and drug developers (100% of revenue).
  • Therapeutic Programs: Preclinical treatments for diseases like hemophilia A, targeting patients with genetic disorders.
  • Collaboration Services: Joint research with companies to develop new therapies, mainly for rare diseases and cancer.
  • Technology Licensing: Access to Metagenomi’s gene editing platform for partners in biotechnology and pharmaceuticals.

Growth Spurts and Strategic Moves

  • Formed a key partnership with Ionis Pharmaceuticals in 2022 for cardiometabolic disease research.
  • Launched a collaboration with Affini-T Therapeutics in 2022 to develop cancer cell therapies.
  • Ended a major agreement with Moderna in April 2024, impacting revenue.
  • Completed its initial public offering (IPO) in February 2024, raising $80.7 million.
  • Established an at-the-market (ATM) equity program in March 2025 for up to $75 million.

Why Metagenomi Stands Out (Without the Lab Coat)

Metagenomi’s platform uses a large database of natural proteins to find new gene editing tools. The company combines artificial intelligence and high-speed screening to improve its technology. Its broad patent portfolio and partnerships help expand its reach in gene therapy research.

Five Things You Need to Know

  • Revenue was $9 million in Q2 2025, down 57.5% from Q2 2024.
  • All revenue in Q2 2025 came from collaboration agreements, not product sales.
  • Operating loss was $21 million in Q2 2025, up 24.5% from Q2 2024.
  • Cash and marketable securities totaled $205 million as of June 30, 2025.
  • Headcount was 171 full-time employees at the end of Q2 2025.

Bottom Line

Metagenomi is an early-stage gene editing company focused on research partnerships and technology development. Its business relies on collaboration revenue and ongoing innovation in genetic medicine.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

119

CEO

Jian Irish, PhD, MBA

Website

www.metagenomi.co

Headquarters

Emeryville, CA 94608, US

MGX Financials

Key Financial Metrics (TTM)

Gross Margin

-16.40%

Operating Margin

-415.48%

Net Income Margin

-384.61%

Return on Equity

-51.23%

Return on Capital

-48.19%

Return on Assets

-43.61%

Earnings Yield

-1.85%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$46.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

37.65M

Volume

13

Avg. Volume

181.82K

Financials (TTM)

Gross Profit

-$3.66M

Operating Income

-$92.78M

EBITDA

-$80.80M

Operating Cash Flow

-$87.23M

Capital Expenditure

-$311.00K

Free Cash Flow

-$87.54M

Cash & ST Invst.

$140.16M

Total Debt

$39.19M

Metagenomi Therapeutics Performance Analysis

Metagenomi Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 17,200,0006978.2%
20232023-12-31USD 44,756,000160.2%
20242024-12-31USD 52,295,00016.8%
20252025-12-31USD 25,210,000-51.8%
Metagenomi Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30106.3%
Q32025-09-301.7%
Q42025-12-31-54.8%
Q12026-03-31-68.1%
Metagenomi Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.16103.3%
20232023-12-31USD -1.8256.6%
20242024-12-31USD -2.0914.5%
20252025-12-31USD -2.3613.1%
Metagenomi Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3020.6%
Q32025-09-30-1.9%
Q42025-12-31-9.1%
Q12026-03-31-1.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$1.25M

-69.8%

Gross Profit

$385.00K

+101.8%

Gross Margin

30.85%

N/A

Market Cap

$46.68MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$395.61K

N/A

Employees

118

N/A

Net Income

-$23.06M

+7.9%

EBITDA

-$21.77M

+7.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$140.16M

-38.0%

Total Debt

$39.19M

-11.8%

Accounts Receivable

$1.00M

-1.2%

Inventory

$0.00

N/A

Long Term Debt

$33.08M

-14.8%

Short Term Debt

$6.11M

+9.0%

Return on Assets

-43.61%

N/A

Return on Invested Capital

-53.18%

N/A

Free Cash Flow

-$21.20M

+8.3%

Operating Cash Flow

-$21.18M

+7.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATYRaTyr Pharma, Inc.
$0.49+0.23%
KLRSKalaris Therapeutics Inc
$4.07+0.74%
QNCXQuince Therapeutics, Inc.
$18.54-1.28%
DTILPrecision BioSciences, Inc.
$7.32-3.94%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$10.28-0.03%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$40.94+0.02%
INTCIntel
$102.62-0.03%
AALAmerican Airlines Group
$14.79-0.03%

Questions About MGX

What is the current price of Metagenomi Therapeutics?

Metagenomi Therapeutics is trading at $1.24 per share.

What is the 52-week range for Metagenomi Therapeutics?

Over the past 52 weeks, Metagenomi Therapeutics has traded between $1.13 and $3.95.

How much debt does Metagenomi Therapeutics have?

As of the most recent reporting period, Metagenomi Therapeutics reported total debt of $39.19M.

How much cash does Metagenomi Therapeutics have on hand?

Metagenomi Therapeutics reported $25.31M in cash and cash equivalents in its most recent financial results.

What is Metagenomi Therapeutics’s dividend yield?

Metagenomi Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services